Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
TUCSON, Ariz., Jan. 27, 2016 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 in New York.
HTG management is scheduled to present at 8:25 a.m. ET. A live audio webcast of the presentation can be accessed by visiting the “Investors” section of HTG’s website at: http://www.htgmolecular.com. The webcast will be available on HTG's website for 90 days following the completion of the presentation.
About HTG Molecular Diagnostics:
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: [email protected]
